Clinical Trial Update: Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

View source ↗

Summary

Clinical trial registry update describing AQP4-positive NMOSD patients treated with Alexion C5 inhibitor therapies; the registry is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• SOLIRIS (eculizumab)
• ULTOMIRIS (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Neuromyelitis Optica Spectrum Disorder, NMOSD | Status: RECRUITING